SCHEMBL4387567

SCHEMBL4387567

CC(=O)Nc1ccc2oc(=O)ccc2c1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.74
▸ GAA P10253 1/20 0.74
▸ KDM4E B2RXH2 6/20 0.71
▸ SMN1; SMN2 Q16637 4/20 0.68
▸ HPGD P15428 3/20 0.62
▸ NPC1 O15118 2/20 0.62
▸ RAB9A P51151 2/20 0.62
▸ HSD17B10 Q99714 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ TP53 P04637 1/20 0.60
▸ CA9 Q16790 5/20 0.59
▸ SNCA P37840 1/20 0.59
▸ CA12 O43570 4/20 0.58
▸ ACHE P22303 2/20 0.58
▸ PPARG P37231 1/20 0.56
▸ NR2E3 Q9Y5X4 1/20 0.56
▸ NCOR2 Q9Y618 1/20 0.56
▸ CA1 P00915 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27886642 0.89 CA9 (0.61) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL13514088 0.86 ALDH1A1 (0.65) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL6952695 0.85 ALDH1A1 (0.68) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL6081510 0.84 ALDH1A1 (0.67) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL12707728 0.83 KMT2A (0.80) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL11236289 0.82 ALDH1A1 (0.64) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL20400281 0.81 ALDH1A1 (1.00) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL13105226 0.80 ALDH1A1 (0.60) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL9317607 0.79 ALDH1A1 (0.61) ALDH1A1GAAKDM4ESMN1; SMN2HPGD
SCHEMBL21788530 0.79 ALDH1A1 (0.64) ALDH1A1GAAKDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006024545-A1 FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2006-03-09 — — WO claimed
US-20240238426-A1 PROTEIN ACYLATION MODULATION BY HETEROBIFUNCTIONAL MOLECULES THE SCRIPPS RESEARCH INSTITUTE 2024-07-18 — — US disclosed
US-7629400-B2 Image making medium HYMAN SYDNEY 2009-12-08 — — US disclosed
US-20060257683-A1 Stainless steel electrolytic coating POLINSKI PAMELA A 2006-11-16 — — US disclosed
WO-2006024545-A1 FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2006-03-09 — — WO disclosed
US-20030178314-A1 Stainless steel electrolytic coating UNITED STATES STEEL CORPORATION 2003-09-25 — — US disclosed
US-20030035917-A1 Image making medium HYMAN SYDNEY (US) 2003-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238426-A1 PROTEIN ACYLATION MODULATION BY HETEROBIFUNCTIONAL MOLECULES ACAT2, ACOT7, AADAC ALDH1A1 1436/4885GAA 1479/4885KDM4E 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback